# Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

> **NCT06523556** · PHASE1,PHASE2 · RECRUITING · sponsor: **Uma Borate** · enrollment: 52 (estimated)

## Conditions studied

- Atypical Chronic Myeloid Leukemia
- Chronic Myelomonocytic Leukemia
- Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myelodysplastic/Myeloproliferative Neoplasm
- Recurrent Myeloproliferative Neoplasm
- Refractory Chronic Myelomonocytic Leukemia
- Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Refractory Myeloproliferative Neoplasm

## Interventions

- **BIOLOGICAL:** Axatilimab
- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration and Biopsy
- **OTHER:** Survey Administration

## Key facts

- **NCT ID:** NCT06523556
- **Lead sponsor:** Uma Borate
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-02
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06523556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06523556, "Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06523556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*